

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**Applicants:** Tracy A. Willson, et al.**Examiner:** Unassigned**Serial No.:** Unassigned**Art Unit:** Unassigned**Filing Date:** Herewith**Docket:** 11373Z**For:** A NOVEL HAEMOPOIETIN RECEPTOR AND
GENETIC SEQUENCES ENCODING SAME**Date:** November 7, 2001Assistant Commissioner for Patents
Washington, DC 20231**PRELIMINARY AMENDMENT**


Sir:

Prior to examination, please amend the above-identified patent application as follows:

IN THE SPECIFICATION:Page 1, after the title, please insert the following:

CERTIFICATE OF MAILING BY "EXPRESS MAIL"**"Express Mail" mailing label number:** EL913702280US**Date of Deposit:** November 7, 2001

I hereby certify that this New Patent Application and Fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, DC 20231.

Dated: November 7, 2001
Peter I. Bernstein

--CROSS REFERENCE TO RELATED APPLICATIONS

The present application is a continuation of application Serial Number 09/051,843 filed October 23, 1996.--

Page 1, line 5, insert the heading --FIELD OF THE INVENTION--;

Page 1, line 11, insert the heading

--BACKGROUND OF THE INVENTION--;

Page 3, line 9, insert the heading --SUMMARY OF THE INVENTION--;

Page 4, line 12, insert the heading --DETAILED DESCRIPTION OF THE INVENTION--;

Please replace the heading beginning at Page 31, line 11 with the following new heading:

[In the Figures] BRIEF DESCRIPTION OF THE DRAWINGS:

IN THE CLAIMS:

Please cancel Claims 1-35 without prejudice, before calculating the filing fee of this continuation application.

Please add the following new Claims:

36. (New) An isolated polypeptide which is capable of binding human IL-13 and/or human IL-4.

37. (New) The isolated polypeptide of Claim 36 comprising SEQ ID NO:4.

38. (New) The isolated polypeptide of Claim 37 comprising a derivative of SEQ ID NO:4.

39. (New) The isolated polypeptide of Claim 38 comprising amino acids 26 to 426 of SEQ ID NO:4.

40. (New) The isolated polypeptide of Claim 38 comprising amino acids 26 to 345 of SEQ ID NO:4.
41. (New) The isolated polypeptide of any one of Claims 36-40 in soluble form.
42. (New) The isolated polypeptide of Claims 36-37 wherein said polypeptide is glycosylated.
43. (New) The isolated polypeptide of Claims 36-37 wherein said polypeptide is unglycosylated.
44. (New) The isolated polypeptide of Claims 36-40 in recombinant form.
45. (New) The isolated polypeptide of Claims 36-38 in mature form.
46. (New) A composition comprising the isolated polypeptide of Claim 36.
47. (New) A composition comprising the isolated polypeptide of Claim 37.
48. (New) A composition comprising the isolated polypeptide of Claim 38.
49. (New) A composition comprising the isolated polypeptide of Claim 39.
50. (New) A composition comprising the isolated polypeptide of Claim 40.
51. (New) The composition of Claims 46-50 further comprising a carrier.

REMARKS

It is respectfully requested that this Preliminary Amendment be entered in this application prior to examination. Early and favorable consideration is requested.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with markings to show changes made."

Respectfully submitted,



Peter I. Bernstein

Registration No. 43,497

SCULLY, SCOTT, MURPHY & PRESSER
400 Garden City Plaza
Garden City, New York 11530
(516) 742-4343
PIB:bg/lf

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION:

Page 1, after the title, please insert the following:

--CROSS REFERENCE TO RELATED APPLICATIONS

The present application is a continuation of application Serial Number
09/051,843 filed October 23, 1996.--

Page 1, line 5, insert the heading --FIELD OF THE INVENTION--;

Page 1, line 11, insert the heading

--BACKGROUND OF THE INVENTION--;

Page 3, line 9, insert the heading --SUMMARY OF THE INVENTION--;

Page 4, line 12, insert the heading --DETAILED DESCRIPTION OF THE
INVENTION--;

Please replace the heading beginning at Page 31, line 11 with the following new heading:

[In the Figures] BRIEF DESCRIPTION OF THE DRAWINGS:

IN THE CLAIMS:

Please cancel Claims 1-35 without prejudice, before calculating the filing fee of this continuation application.

Please add the following new Claims:

36. (New) An isolated polypeptide which is capable of binding human IL-13
and/or human IL-4.

37. (New) The isolated polypeptide of Claim 36 comprising SEQ ID NO:4.

38. (New) The isolated polypeptide of Claim 37 comprising a derivative of
SEQ ID NO:4.

39. (New) The isolated polypeptide of Claim 38 comprising amino acids 26 to 426 of SEQ ID NO:4.

40. (New) The isolated polypeptide of Claim 38 comprising amino acids 26 to 345 of SEQ ID NO:4.

41. (New) The isolated polypeptide of any one of Claims 36-40 in soluble form.

42. (New) The isolated polypeptide of Claims 36-37 wherein said polypeptide is glycosylated.

43. (New) The isolated polypeptide of Claims 36-37 wherein said polypeptide is unglycosylated.

44. (New) The isolated polypeptide of Claims 36-40 in recombinant form.

45. (New) The isolated polypeptide of Claims 36-38 in mature form.

46. (New) A composition comprising the isolated polypeptide of Claim 36.

47. (New) A composition comprising the isolated polypeptide of Claim 37.

48. (New) A composition comprising the isolated polypeptide of Claim 38.

49. (New) A composition comprising the isolated polypeptide of Claim 39.

50. (New) A composition comprising the isolated polypeptide of Claim 40.

51. (New) The composition of Claims 46-50 further comprising a carrier.